134 References 1. Grunewald J, Grutters JC, Arkema E V., Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Prim. 2019;5(1). doi:10.1038/s41572-019-0096-x 2. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;103(3):527-534. doi:10.1016/j.mcna.2018.12.011 3. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Hear Rhythm. 2014;11(7):1304-1323. doi:10.1016/j.hrthm.2014.03.043 4. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795-802. doi:10.1164/rccm.200603-402OC 5. Voortman M, Hendriks CMR, Elfferich MDP, et al. The burden of sarcoidosis symptoms from a patient perspective. Lung. 2019;197(2):155-161. doi:10.1007/s00408-019-00206-7 6. Voortman M, Fritz D, Vogels OJM, et al. Small fiber neuropathy: A disabling and underrecognized syndrome. Curr Opin Pulm Med. 2017;23(5):447-457. doi:10.1097/MCP.0000000000000413 7. Gavrilova N, Starshinova A, Zinchenko Y, et al. Small fiber neuropathy in sarcoidosis. Pathophysiology. 2021;28(4):544-550. doi:10.3390/pathophysiology28040035 8. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997-1004. doi:10.1378/chest.125.3.997 9. De Vries J, Wirnsberger RM. Fatigue, quality of life and health status in sarcoidosis. Sarcoidosis. 2010:92-104. doi:10.1183/1025448x.00032007 10. Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43(6):1730-1739. doi:10.1183/09031936.00169413 11. Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017;126:135-138. doi:10.1016/j.rmed.2017.03.011 12. Van Velzen M, Heij L, Niesters M, et al. Ara 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs. 2014;23(4):541-550. doi:10.1517/13543784.2014.892072 13. Vorselaars ADM, Crommelin HA, Deneer VHM, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175-185. doi:10.1183/09031936.00227014 14. Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36(7):1131-1137. doi:10.1007/s00259-009-1097-x 15. Costabel U, Hunninghake GW, Statement S. EDITORIAL ATS / ERS / WASOG statement on sarcoidosis. Eur Respir J. 1999;14(4):735-737. doi:10.1034/j.1399-3003.1999.14d02.x 16. Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med. 2011;105(1):95-100. doi:10.1016/j.rmed.2010.09.014 17. Voortman M, Beekman E, Drent M, Hoitsma E, De Vries J. Determination of the smallest detectable change (SDC) and the minimal important difference (MID) for the small fiber neuropathy screening list (SFNSL) in sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. 2018;35(4):333-341. 18. Keijsers RGM, Van Den Heuve DAF, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J. 2013;41(3):743-751. doi:10.1183/09031936.00088612 19. Adams H, Keijsers RG, Korenromp IHE, Grutters JC. FDG PET for gauging of sarcoid disease activity. Semin Respir Crit Care Med. 2014;35(3):352-361. doi:10.1055/s-0034-1376866 8 140 8
RkJQdWJsaXNoZXIy MjY0ODMw